Luc Dupuis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2827106/publications.pdf

Version: 2024-02-01

79	5,714	76326	82547
papers	citations	40 h-index	72 g-index

87	87	87	6035
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11159-11164.	7.1	479
2	Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 75-82.	10.2	457
3	Sodium Valproate Exerts Neuroprotective EffectsIn Vivothrough CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse Model. Journal of Neuroscience, 2007, 27, 5535-5545.	3.6	196
4	Toxic gain of function from mutant <scp>FUS</scp> protein is crucial to trigger cell autonomous motor neuron loss. EMBO Journal, 2016, 35, 1077-1097.	7.8	187
5	Muscle Mitochondrial Uncoupling Dismantles Neuromuscular Junction and Triggers Distal Degeneration of Motor Neurons. PLoS ONE, 2009, 4, e5390.	2.5	176
6	Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Current Opinion in Pharmacology, 2009, 9, 341-346.	3.5	172
7	Nogo Provides a Molecular Marker for Diagnosis of Amyotrophic Lateral Sclerosis. Neurobiology of Disease, 2002, 10, 358-365.	4.4	152
8	Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 166-171.	2.1	139
9	The neurite outgrowth inhibitor Nogoâ€A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Reports, 2006, 7, 1162-1167.	4.5	135
10	Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 19-32.	1.7	135
11	Nogo-A, -B, and -C Are Found on the Cell Surface and Interact Together in Many Different Cell Types. Journal of Biological Chemistry, 2005, 280, 12494-12502.	3.4	134
12	Mitochondria in Amyotrophic Lateral Sclerosis: A Trigger and a Target. Neurodegenerative Diseases, 2004, 1, 245-254.	1.4	133
13	The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathology, 2016, 26, 227-236.	4.1	133
14	A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e37885.	2.5	125
15	Upâ€regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB Journal, 2003, 17, 1-19.	0.5	117
16	Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiological Genomics, 2008, 32, 207-218.	2.3	115
17	A plural role for lipids in motor neuron diseases: energy, signaling and structure. Frontiers in Cellular Neuroscience, 2014, 8, 25.	3.7	114
18	Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Annals of Neurology, 2005, 57, 553-556.	5.3	113

#	Article	IF	Citations
19	Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1033-1041.	1.9	113
20	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. Frontiers in Molecular Neuroscience, 2018, 11, 2.	2.9	113
21	Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathologica, 2017, 133, 887-906.	7.7	111
22	Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. Journal of Lipid Research, 2007, 48, 1571-1580.	4.2	106
23	Effect of Highâ€Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Annals of Neurology, 2020, 87, 206-216.	5.3	105
24	Cytoplasmic dynein in neurodegeneration. , 2011, 130, 348-363.		92
25	Muscle Nogo-a expression is a prognostic marker in lower motor neuron syndromes. Annals of Neurology, 2007, 62, 15-20.	5.3	82
26	Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. European Journal of Epidemiology, 2017, 32, 901-908.	5.7	82
27	FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nature Neuroscience, 2019, 22, 1793-1805.	14.8	81
28	Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. Journal of Neurology, 2015, 262, 849-858.	3.6	80
29	Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain, 2016, 139, 1106-1122.	7.6	80
30	Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 2350-2360.	2.9	75
31	PGC-1Â is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 3477-3484.	2.9	74
32	Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e67783.	2.5	74
33	Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: a link to spasticity. Brain, 2013, 136, 483-493.	7.6	72
34	Amyotrophic lateral sclerosis: all roads lead to Rome. Journal of Neurochemistry, 2007, 101, 1153-1160.	3.9	71
35	Mice with a mutation in the dynein heavy chain 1 gene display sensory neuropathy but lack motor neuron disease. Experimental Neurology, 2009, 215, 146-152.	4.1	61
36	A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Human Molecular Genetics, 2010, 19, 4385-4398.	2.9	55

#	Article	IF	Citations
37	Differential Screening of Mutated SOD1 Transgenic Mice Reveals Early Up-Regulation of a Fast Axonal Transport Component in Spinal Cord Motor Neurons. Neurobiology of Disease, 2000, 7, 274-285.	4.4	53
38	Platelet Serotonin Level Predicts Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2010, 5, e13346.	2.5	49
39	Hypertonic Stress Causes Cytoplasmic Translocation of Neuronal, but Not Astrocytic, FUS due to Impaired Transportin Function. Cell Reports, 2018, 24, 987-1000.e7.	6.4	49
40	Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis â€“ results from a population- based ALS registry in Germany. Scientific Reports, 2017, 7, 4374.	3.3	45
41	Mitochondrial quality control in neurodegenerative diseases. Biochimie, 2014, 100, 177-183.	2.6	44
42	Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. Acta Neuropathologica, 2016, 131, 465-480.	7.7	41
43	Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Experimental Neurology, 2018, 299, 15-25.	4.1	41
44	Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments. Current Drug Targets, 2010, 11, 1250-1261.	2.1	41
45	Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age. Neurobiology of Disease, 2013, 58, 220-230.	4.4	40
46	Synaptic FUS accumulation triggers early misregulation of synaptic RNAs in a mouse model of ALS. Nature Communications, 2021, 12, 3027.	12.8	39
47	VAPB/ALS8 MSP Ligands Regulate Striated Muscle Energy Metabolism Critical for Adult Survival in Caenorhabditis elegans. PLoS Genetics, 2013, 9, e1003738.	3.5	35
48	ALS-causing mutations differentially affect PGC-1Î± expression and function in the brain vs. peripheral tissues. Neurobiology of Disease, 2017, 97, 36-45.	4.4	35
49	Role of RNA Binding Proteins with prion-like domains in muscle and neuromuscular diseases. Cell Stress, 2020, 4, 76-91.	3.2	35
50	The metabolic hypothesis in amyotrophic lateral sclerosis: insights from mutant Cu/Zn-superoxide dismutase mice. Biomedicine and Pharmacotherapy, 2005, 59, 190-196.	5.6	33
51	Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 444-456.	5.3	30
52	Cytoplasmic FUS triggers early behavioral alterations linked to cortical neuronal hyperactivity and inhibitory synaptic defects. Nature Communications, 2021, 12, 3028.	12.8	28
53	Systemic Down-Regulation of Delta-9 Desaturase Promotes Muscle Oxidative Metabolism and Accelerates Muscle Function Recovery following Nerve Injury. PLoS ONE, 2013, 8, e64525.	2.5	27
54	Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2018, 75, 600.	9.0	24

#	Article	IF	Citations
55	Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression. Neurobiology of Disease, 2021, 152, 105289.	4.4	24
56	Low dietary protein content alleviates motor symptoms in mice with mutant dynactin/dynein-mediated neurodegeneration. Human Molecular Genetics, 2015, 24, 2228-2240.	2.9	22
57	Mutations in cytoplasmic dynein lead to a Huntington's disease-like defect in energy metabolism of brown and white adipose tissues. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 59-69.	3.8	20
58	Paradox of amyotrophic lateral sclerosis and energy metabolism. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1013-1014.	1.9	20
59	Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis â€“ Results from the ALS Registry Swabia. Scientific Reports, 2020, 10, 736.	3.3	19
60	Adipose Tissue Distribution in Patients withÂAlzheimerâ€™s Disease: A Whole Body MRI Case-Control Study. Journal of Alzheimer's Disease, 2015, 48, 825-832.	2.6	18
61	Body fat distribution in Parkinson's disease: An MRI-based body fat quantification study. Parkinsonism and Related Disorders, 2016, 33, 84-89.	2.2	18
62	Multiplexed chemogenetics in astrocytes and motoneurons restore bloodâ€“spinal cord barrier in ALS. Life Science Alliance, 2020, 3, e201900571.	2.8	18
63	A mutation in the dynein heavy chain gene compensates for energy deficit of mutant SOD1 mice and increases potentially neuroprotective IGF-1. Molecular Neurodegeneration, 2011, 6, 26.	10.8	15
64	Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients. Translational Neurodegeneration, 2021, 10, 17.	8.0	15
65	Dysregulation of energy homeostasis in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2021, 34, 773-780.	3.6	11
66	The dark side of HDAC inhibition in ALS. EBioMedicine, 2019, 41, 38-39.	6.1	10
67	Oxidative stress sensitivity in ALS muscle cells. Experimental Neurology, 2009, 220, 219-223.	4.1	9
68	Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease. Movement Disorders, 2019, 34, 1566-1570.	3.9	9
69	Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation. Molecular Neurodegeneration, 2021, 16, 61.	10.8	9
70	Thermoregulation in amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 749-760.	1.8	7
71	Hypothalamus and weight loss in amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 180, 327-338.	1.8	7
72	Thermoregulatory disorders in Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 761-775.	1.8	6

#	Article	IF	Citations
73	Evaluation of a 5-HT2B receptor agonist in a murine model of amyotrophic lateral sclerosis. Scientific Reports, 2021, 11, 23582.	3.3	5
74	Progranulin Bridges Energy Homeostasis and Fronto-Temporal Dementia. Cell Metabolism, 2012, 15, 269-270.	16.2	4
75	Full-length PGC-1Î± salvages the phenotype of a mouse model of human neuropathy through mitochondrial proliferation. Human Molecular Genetics, 2013, 22, 5096-5106.	2.9	3
76	Unmasking the skiptic task of TDPâ€43. EMBO Journal, 2018, 37, .	7.8	3
77	Linking neuroinflammation to motor neuron degeneration in ALS: The critical role of CXCL13/CXCR5. EBioMedicine, 2021, 63, 103149.	6.1	3
78	Neuroprotective Strategies in Amyotrophic Lateral Sclerosis: Modulation of Neurotransmittory and Neurotrophic Input to Motor Neurons. , 2014, , 1417-1434.		0
79	Serotonin and the 5-HT2B Receptor in Amyotrophic Lateral Sclerosis. Receptors, 2021, , 367-386.	0.2	0